Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ELTX Elicio Therapeutics

盘前交易 11-15 08:24:32 EST

5.45

+0.25

+4.81%

最高5.81	最低5.20	成交量5.10万
今开5.20	昨收5.20	日振幅11.73%
总市值5,872万	流通市值4,600万	总股本1,077万
成交额27.86万	换手率0.60%	流通股本844.05万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":5.45,"timestamp":1731618000000,"preClose":5.2,"halted":0,"volume":51015,"delay":0,"floatShares":8440500,"shares":10774574,"eps":-4.01171,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.25,"latestTime":"11-15 08:24:32 EST","open":5.2,"high":5.8099,"low":5.1999,"amount":278626.5849,"amplitude":0.117308,"askPrice":5.8,"askSize":66,"bidPrice":4.7,"bidSize":52,"shortable":3,"etf":0,"ttmEps":-4.01171,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731681000000},"adr":0,"listingDate":1612501200000,"adjPreClose":5.45,"postHourTrading":{"tag":"盘后","latestPrice":5.45,"preClose":5.45,"latestTime":"16:00 EST","volume":4,"amount":21.8,"timestamp":1731618001868},"volumeRatio":2.5860233638550296},"requestUrl":"/m/hq/s/ELTX","defaultTab":"news","newsList":[{"id":"2483372804","title":"Elicio Therapeutics, Inc.盘中异动 快速上涨7.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483372804","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483372804?lang=zh_cn&edition=full","pubTime":"2024-11-14 22:36","pubTimestamp":1731594972,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日22时36分，Elicio Therapeutics, Inc.股票出现异动，股价快速上涨7.86%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.47%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114223612971a68f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114223612971a68f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2482438579","title":"Elicio Therapeutics, Inc.盘中异动 急速拉升5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482438579","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482438579?lang=zh_cn&edition=full","pubTime":"2024-11-09 01:40","pubTimestamp":1731087651,"startTime":"0","endTime":"0","summary":"北京时间2024年11月09日01时40分，Elicio Therapeutics, Inc.股票出现异动，股价急速上涨5.21%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.05%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109014052a2252ef4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109014052a2252ef4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELTX","BK4007","LENZ"],"gpt_icon":0},{"id":"2481604046","title":"Elicio Therapeutics Inc  预计每股亏损 73 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2481604046","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481604046?lang=zh_cn&edition=full","pubTime":"2024-11-06 21:56","pubTimestamp":1730901396,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc  预计每股亏损 73 美分 - 财报前瞻Elicio Therapeutics Inc ELTX.OQ ELTX.O预计在11月7日公布截至0001年1月1日的业绩时，季度收入将没有变化(预计)。LSEG 的分析师平均预计 Elicio Therapeutics Inc 每股亏损 73 美分。华尔街对 Elicio Therapeutics Inc 的 12 个月目标价中位数为 9.50 美元，高于其最新收盘价 4.84 美元。11月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。如有任何其他问题或反馈，请联系 RefinitivNewsSupport@thomsonreuters.com。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL4T3MD281:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2481682684","title":"Elicio Therapeutics, Inc.盘中异动 早盘快速上涨5.21%报4.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481682684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481682684?lang=zh_cn&edition=full","pubTime":"2024-11-05 23:59","pubTimestamp":1730822343,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日23时59分，Elicio Therapeutics, Inc.股票出现波动，股价急速拉升5.21%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110523590498e4096a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110523590498e4096a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ELTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2480584758","title":"Elicio Therapeutics, Inc.盘中异动 早盘股价大跌7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480584758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480584758?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:53","pubTimestamp":1730732003,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日22时53分，Elicio Therapeutics, Inc.股票出现异动，股价大幅下跌7.88%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104225324971a42cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104225324971a42cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2480832110","title":"Elicio Therapeutics, Inc.盘中异动 股价大涨7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480832110","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480832110?lang=zh_cn&edition=full","pubTime":"2024-11-02 00:45","pubTimestamp":1730479532,"startTime":"0","endTime":"0","summary":"北京时间2024年11月02日00时45分，Elicio Therapeutics, Inc.股票出现异动，股价大幅上涨7.75%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.62%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110200453298e400f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110200453298e400f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","ELTX","LENZ"],"gpt_icon":0},{"id":"2479164033","title":"Elicio Therapeutics, Inc.盘中异动 大幅拉升5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479164033","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479164033?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:47","pubTimestamp":1730382478,"startTime":"0","endTime":"0","summary":"北京时间2024年10月31日21时47分，Elicio Therapeutics, Inc.股票出现波动，股价快速拉升5.77%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.39%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121475898e3fb83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121475898e3fb83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","ELTX","LENZ"],"gpt_icon":0},{"id":"2479236206","title":"Elicio Therapeutics, Inc.盘中异动 急速下挫7.48%报4.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479236206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479236206?lang=zh_cn&edition=full","pubTime":"2024-10-30 00:29","pubTimestamp":1730219396,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日00时29分，Elicio Therapeutics, Inc.股票出现异动，股价急速下挫7.48%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103000295698e3f276&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103000295698e3f276&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2478480169","title":"Elicio Therapeutics, Inc.盘中异动 股价大跌5.27%报4.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478480169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478480169?lang=zh_cn&edition=full","pubTime":"2024-10-28 23:03","pubTimestamp":1730127839,"startTime":"0","endTime":"0","summary":"北京时间2024年10月28日23时03分，Elicio Therapeutics, Inc.股票出现异动，股价大幅下挫5.27%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.41%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102823040098e3eddb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102823040098e3eddb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","ELTX","LENZ"],"gpt_icon":0},{"id":"2478664099","title":"Elicio Therapeutics, Inc.盘中异动 大幅下挫5.65%报4.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478664099","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478664099?lang=zh_cn&edition=full","pubTime":"2024-10-26 03:49","pubTimestamp":1729885774,"startTime":"0","endTime":"0","summary":"北京时间2024年10月26日03时49分，Elicio Therapeutics, Inc.股票出现波动，股价快速下跌5.65%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.57%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241026034934a1eb33ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241026034934a1eb33ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ELTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2476992078","title":"Elicio Therapeutics, Inc.盘中异动 股价大涨5.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476992078","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476992078?lang=zh_cn&edition=full","pubTime":"2024-10-17 04:01","pubTimestamp":1729108910,"startTime":"0","endTime":"0","summary":"北京时间2024年10月17日04时01分，Elicio Therapeutics, Inc.股票出现波动，股价大幅拉升5.79%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.67%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241017040151a1e1297f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241017040151a1e1297f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELTX","BK4007","LENZ"],"gpt_icon":0},{"id":"2474620677","title":"Elicio Therapeutics, Inc.盘中异动 临近收盘快速拉升8.21%报5.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474620677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474620677?lang=zh_cn&edition=full","pubTime":"2024-10-10 03:46","pubTimestamp":1728503162,"startTime":"0","endTime":"0","summary":"北京时间2024年10月10日03时46分，Elicio Therapeutics, Inc.股票出现异动，股价急速上涨8.21%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101003460298e3b86f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101003460298e3b86f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2472396910","title":"Elicio Therapeutics, Inc.盘中异动 早盘急速跳水5.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472396910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472396910?lang=zh_cn&edition=full","pubTime":"2024-10-04 23:25","pubTimestamp":1728055526,"startTime":"0","endTime":"0","summary":"北京时间2024年10月04日23时25分，Elicio Therapeutics, Inc.股票出现波动，股价急速跳水5.53%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100423252698e3aa17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100423252698e3aa17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","ELTX"],"gpt_icon":0},{"id":"2470459934","title":"Elicio Therapeutics, Inc.盘中异动 下午盘急速下挫7.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470459934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470459934?lang=zh_cn&edition=full","pubTime":"2024-09-25 02:59","pubTimestamp":1727204364,"startTime":"0","endTime":"0","summary":"北京时间2024年09月25日02时59分，Elicio Therapeutics, Inc.股票出现波动，股价急速下跌7.23%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.39%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092502592498e38b68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092502592498e38b68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","ELTX","LENZ"],"gpt_icon":0},{"id":"2460736385","title":"Elicio Therapeutics, Inc.2024财年第二财季实现净利润-7.23百万美元，同比增加4.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460736385","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460736385?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:04","pubTimestamp":1723910671,"startTime":"0","endTime":"0","summary":"8月18日，Elicio Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-7.23百万美元，同比增加4.37%；其中营业收入为0.00美元，每股基本收益为-0.64美元。机构评级：截至2024年8月18日，当前有1家机构对Elicio Therapeutics, Inc.目标价做出预测，其中目标均价为10.00美元，其中最低目标价为10.00美元，最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800070895a16836&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800070895a16836&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","LENZ"],"gpt_icon":0},{"id":"2457682811","title":"Elicio Therapeutics Inc    预计每股亏损 96 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457682811","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457682811?lang=zh_cn&edition=full","pubTime":"2024-08-07 23:02","pubTimestamp":1723042928,"startTime":"0","endTime":"0","summary":"   * Elicio Therapeutics Inc    预计在8月9日公布截至2024年6月30日的财报时，季度营收将不会有任何变化(预计)    *    * LSEG 的分析师平均预计 Elicio Therapeutics Inc 每股亏损 96 美分。* 华尔街对 Elicio Therapeutics Inc 的 12 个月目标价中位数为 10.00 美元，高于其上次收盘价 4.40 美元。8月7日 - 本摘要于北京时间 8 月 7 日 15:02 机器生成。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","LENZ"],"gpt_icon":0},{"id":"2446078365","title":"Elicio Therapeutics宣布定价1150万美元的担保公开发行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446078365","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446078365?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:00","pubTimestamp":1719579600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ELTX","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2446567047","title":"Elicio Therapeutics Inc-用于开发管线的款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2446567047","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446567047?lang=zh_cn&edition=full","pubTime":"2024-06-28 04:05","pubTimestamp":1719518755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","ELTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2446567706","title":"Elicio Therapeutics宣布拟提出公开发行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446567706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446567706?lang=zh_cn&edition=full","pubTime":"2024-06-28 04:05","pubTimestamp":1719518700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ELTX","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2446674205","title":"Elicio Therapeutics宣布Eli-002 7P开展Amplify-7P 1a期研究的初步无病生存分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2446674205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446674205?lang=zh_cn&edition=full","pubTime":"2024-06-28 04:01","pubTimestamp":1719518465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","ELTX","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://elicio.com","stockEarnings":[{"period":"1week","weight":0.1822},{"period":"1month","weight":0.2138},{"period":"3month","weight":0.2386},{"period":"6month","weight":-0.4577},{"period":"1year","weight":-0.1036},{"period":"ytd","weight":-0.3465}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Elicio Therapeutics Inc于1998年4月6日在特拉华州成立。该公司是一家临床阶段的生物技术公司，正在开发一系列新型免疫疗法，用于治疗癌症和其他疾病。通过结合免疫学和免疫疗法方面的专业知识，Elicio正在设计研究性两亲（AMP）免疫疗法，旨在精确地靶向和完全接合淋巴结。Elicio是工程淋巴结靶向为一系列侵袭性癌症和传染病生产AMPlifiers，免疫调节剂，佐剂，和疫苗。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.218043},{"month":2,"riseRate":0,"avgChangeRate":-0.16654},{"month":3,"riseRate":0.75,"avgChangeRate":0.240014},{"month":4,"riseRate":0.5,"avgChangeRate":-0.026973},{"month":5,"riseRate":0.75,"avgChangeRate":0.162305},{"month":6,"riseRate":0,"avgChangeRate":-0.254842},{"month":7,"riseRate":0.5,"avgChangeRate":0.007352},{"month":8,"riseRate":0.25,"avgChangeRate":-0.105324},{"month":9,"riseRate":0.5,"avgChangeRate":0.034006},{"month":10,"riseRate":0.25,"avgChangeRate":-0.21101},{"month":11,"riseRate":0.25,"avgChangeRate":-0.023567},{"month":12,"riseRate":0.333333,"avgChangeRate":0.039614}],"exchange":"NASDAQ","name":"Elicio Therapeutics","nameEN":"Elicio Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Elicio Therapeutics,ELTX,Elicio Therapeutics股票,Elicio Therapeutics股票老虎,Elicio Therapeutics股票老虎国际,Elicio Therapeutics行情,Elicio Therapeutics股票行情,Elicio Therapeutics股价,Elicio Therapeutics股市,Elicio Therapeutics股票价格,Elicio Therapeutics股票交易,Elicio Therapeutics股票购买,Elicio Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}